(Source: Business Wire)
XenoPort, Inc. (Nasdaq:XNPT) announced today that it is offering to sell, subject to market and other conditions, 2,500,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. XenoPort also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 375,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by XenoPort. Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. are acting as joint book-runners for the offering.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, New York, New York 10014 (Email prospectus@morganstanley.com) or Goldman, Sachs & Co., Attn: Registration Department, 85 Broad Street, 20th Floor, New York, New York, 10004 (Telephone number 1-866-471-2526 or prospectus-ny@ny.email.gs.com).
The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate, XP13512, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. The Food and Drug Administration is currently reviewing the new drug application for this product candidate as a potential treatment for moderate-to-severe primary restless legs syndrome.
